Dr. Roberta Diaz Brinton, Inaugural Director of the Center for Innovation in Brain Science at the University of Arizona Health Sciences, and Professor of Pharmacology and Neurology at the U of A College of Medicine, will discuss her phase 2 clinical trial using allopregnanolone, a neurosteroid derived from progesterone, to spur the generation of new brain cells and restore lost cognitive function in Alzheimer’s patients, a process called “neurogenesis.” The ADDF has funded Dr. Brinton’s work since 2004 and awarded her the Melvin R. Goodes Prize in 2017.
“Tomorrow’s Breakthroughs Today” features world-class scientists discussing the path toward new, cutting-edge treatments for Alzheimer’s disease. Now in its fifth season, this lecture series invites three top investigators to share the latest breaking updates on their research with moderator Dr. Howard Fillit, Co-Founder and Chief Science Officer of the Alzheimer’s Drug Discovery Foundation (ADDF). Founded in 1998 by Leonard A. and Ronald S. Lauder, the ADDF is dedicated to rapidly accelerating the development of novel therapeutics and biomarkers to prevent, treat, and cure Alzheimer’s disease and related dementias.
Presented by the Alzheimer’s Drug Discovery Foundation in partnership with Heidi and Tom McWilliams
